Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 268

1.

TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates.

Laferrière F, Maniecka Z, Pérez-Berlanga M, Hruska-Plochan M, Gilhespy L, Hock EM, Wagner U, Afroz T, Boersema PJ, Barmettler G, Foti SC, Asi YT, Isaacs AM, Al-Amoudi A, Lewis A, Stahlberg H, Ravits J, De Giorgi F, Ichas F, Bezard E, Picotti P, Lashley T, Polymenidou M.

Nat Neurosci. 2019 Jan;22(1):65-77. doi: 10.1038/s41593-018-0294-y. Epub 2018 Dec 17.

PMID:
30559480
2.

RGS9-2 rescues dopamine D2 receptor levels and signaling in DYT1 dystonia mouse models.

Bonsi P, Ponterio G, Vanni V, Tassone A, Sciamanna G, Migliarini S, Martella G, Meringolo M, Dehay B, Doudnikoff E, Zachariou V, Goodchild RE, Mercuri NB, D'Amelio M, Pasqualetti M, Bezard E, Pisani A.

EMBO Mol Med. 2019 Jan;11(1). pii: e9283. doi: 10.15252/emmm.201809283.

3.

Harnessing Lysosomal pH through PLGA Nanoemulsion as a Treatment of Lysosomal-Related Neurodegenerative Diseases.

Prévot G, Soria FN, Thiolat ML, Daniel J, Verlhac JB, Blanchard-Desce M, Bezard E, Barthélémy P, Crauste-Manciet S, Dehay B.

Bioconjug Chem. 2018 Nov 27. doi: 10.1021/acs.bioconjchem.8b00697. [Epub ahead of print]

PMID:
30424597
4.

The hidden side of Parkinson's disease: Studying pain, anxiety and depression in animal models.

Faivre F, Joshi A, Bezard E, Barrot M.

Neurosci Biobehav Rev. 2019 Jan;96:335-352. doi: 10.1016/j.neubiorev.2018.10.004. Epub 2018 Oct 23. Review.

PMID:
30365972
5.

Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts.

Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH, Bezard E, Picconi B, Calabresi P, Lang AE.

Ann Neurol. 2018 Dec;84(6):797-811. doi: 10.1002/ana.25364. Epub 2018 Nov 30. Review.

PMID:
30357892
6.

Meta-analysis of amantadine efficacy for improving preclinical research reliability.

Stanley P, Pioli EY, Kozak R, Popiolek M, Bezard E.

Mov Disord. 2018 Oct;33(10):1555-1557. doi: 10.1002/mds.27486. Epub 2018 Oct 4. No abstract available.

PMID:
30288778
7.

NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology.

Mellone M, Zianni E, Stanic J, Campanelli F, Marino G, Ghiglieri V, Longhi A, Thiolat ML, Li Q, Calabresi P, Bezard E, Picconi B, Di Luca M, Gardoni F.

Neurobiol Dis. 2019 Jan;121:338-349. doi: 10.1016/j.nbd.2018.09.021. Epub 2018 Sep 24.

PMID:
30261285
8.

An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates.

Charvin D, Di Paolo T, Bezard E, Gregoire L, Takano A, Duvey G, Pioli E, Halldin C, Medori R, Conquet F.

Mov Disord. 2018 Oct;33(10):1619-1631. doi: 10.1002/mds.27462. Epub 2018 Sep 14.

PMID:
30216534
9.

Configuration of electrical spinal cord stimulation through real-time processing of gait kinematics.

Capogrosso M, Wagner FB, Gandar J, Moraud EM, Wenger N, Milekovic T, Shkorbatova P, Pavlova N, Musienko P, Bezard E, Bloch J, Courtine G.

Nat Protoc. 2018 Sep;13(9):2031-2061. doi: 10.1038/s41596-018-0030-9.

PMID:
30190556
10.

G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice.

Novello S, Arcuri L, Dovero S, Dutheil N, Shimshek DR, Bezard E, Morari M.

Neurobiol Dis. 2018 Dec;120:21-33. doi: 10.1016/j.nbd.2018.08.018. Epub 2018 Aug 30.

PMID:
30172844
11.

Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing.

Boland B, Yu WH, Corti O, Mollereau B, Henriques A, Bezard E, Pastores GM, Rubinsztein DC, Nixon RA, Duchen MR, Mallucci GR, Kroemer G, Levine B, Eskelinen EL, Mochel F, Spedding M, Louis C, Martin OR, Millan MJ.

Nat Rev Drug Discov. 2018 Sep;17(9):660-688. doi: 10.1038/nrd.2018.109. Epub 2018 Aug 17. Review.

PMID:
30116051
12.

Systemic Gene Delivery by Single-Dose Intracardiac Administration of scAAV2/9 and scAAV2/rh10 Variants in Newborn Rats.

Chansel-Debordeaux L, Bourdenx M, Dutheil N, Dovero S, Canron MH, Jimenez C, Bezard E, Dehay B.

Hum Gene Ther Methods. 2018 Aug;29(4):189-199. doi: 10.1089/hgtb.2017.192.r3.

PMID:
30064266
13.

The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia.

Rojo-Bustamante E, Abellanas MA, Clavero P, Thiolat ML, Li Q, Luquin MR, Bezard E, Aymerich MS.

Neurobiol Dis. 2018 Oct;118:64-75. doi: 10.1016/j.nbd.2018.06.019. Epub 2018 Jun 21.

PMID:
29936234
14.

Cardinal Motor Features of Parkinson's Disease Coexist with Peak-Dose Choreic-Type Drug-Induced Dyskinesia.

Goubault E, Nguyen HP, Bogard S, Blanchet PJ, Bézard E, Vincent C, Langlois M, Duval C.

J Parkinsons Dis. 2018;8(2):323-331. doi: 10.3233/JPD-181312.

15.

Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.

Baufreton J, Milekovic T, Li Q, McGuire S, Moraud EM, Porras G, Sun S, Ko WKD, Chazalon M, Morin S, Normand E, Farjot G, Milet A, Pype J, Pioli E, Courtine G, Bessière B, Bezard E.

Mov Disord. 2018 Oct;33(10):1632-1642. doi: 10.1002/mds.27404. Epub 2018 May 14.

16.

The Tyrosine Phosphatase STEP Is Involved in Age-Related Memory Decline.

Castonguay D, Dufort-Gervais J, Ménard C, Chatterjee M, Quirion R, Bontempi B, Schneider JS, Arnsten AFT, Nairn AC, Norris CM, Ferland G, Bézard E, Gaudreau P, Lombroso PJ, Brouillette J.

Curr Biol. 2018 Apr 2;28(7):1079-1089.e4. doi: 10.1016/j.cub.2018.02.047. Epub 2018 Mar 22.

PMID:
29576474
17.

Pharmacological Inhibition of Necroptosis Protects from Dopaminergic Neuronal Cell Death in Parkinson's Disease Models.

Iannielli A, Bido S, Folladori L, Segnali A, Cancellieri C, Maresca A, Massimino L, Rubio A, Morabito G, Caporali L, Tagliavini F, Musumeci O, Gregato G, Bezard E, Carelli V, Tiranti V, Broccoli V.

Cell Rep. 2018 Feb 20;22(8):2066-2079. doi: 10.1016/j.celrep.2018.01.089.

18.

Synaptic Regulator α-Synuclein in Dopaminergic Fibers Is Essentially Required for the Maintenance of Subependymal Neural Stem Cells.

Perez-Villalba A, Sirerol-Piquer MS, Belenguer G, Soriano-Cantón R, Muñoz-Manchado AB, Villadiego J, Alarcón-Arís D, Soria FN, Dehay B, Bezard E, Vila M, Bortolozzi A, Toledo-Aral JJ, Pérez-Sánchez F, Fariñas I.

J Neurosci. 2018 Jan 24;38(4):814-825. doi: 10.1523/JNEUROSCI.2276-17.2017. Epub 2017 Dec 7.

19.

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, Burn D, Halliday GM, Bezard E, Przedborski S, Lehericy S, Brooks DJ, Rothwell JC, Hallett M, DeLong MR, Marras C, Tanner CM, Ross GW, Langston JW, Klein C, Bonifati V, Jankovic J, Lozano AM, Deuschl G, Bergman H, Tolosa E, Rodriguez-Violante M, Fahn S, Postuma RB, Berg D, Marek K, Standaert DG, Surmeier DJ, Olanow CW, Kordower JH, Calabresi P, Schapira AHV, Stoessl AJ.

Mov Disord. 2017 Sep;32(9):1264-1310. doi: 10.1002/mds.27115. Review.

20.

In utero delivery of rAAV2/9 induces neuronal expression of the transgene in the brain: towards new models of Parkinson's disease.

Chansel-Debordeaux L, Bourdenx M, Dovero S, Grouthier V, Dutheil N, Espana A, Groc L, Jimenez C, Bezard E, Dehay B.

Gene Ther. 2017 Dec;24(12):801-809. doi: 10.1038/gt.2017.84. Epub 2017 Nov 16.

PMID:
28853717
21.

Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias.

Stanic J, Mellone M, Napolitano F, Racca C, Zianni E, Minocci D, Ghiglieri V, Thiolat ML, Li Q, Longhi A, De Rosa A, Picconi B, Bezard E, Calabresi P, Di Luca M, Usiello A, Gardoni F.

Neurobiol Dis. 2017 Dec;108:54-64. doi: 10.1016/j.nbd.2017.08.001. Epub 2017 Aug 18.

22.

Mitochondrial division inhibitor-1 is neuroprotective in the A53T-α-synuclein rat model of Parkinson's disease.

Bido S, Soria FN, Fan RZ, Bezard E, Tieu K.

Sci Rep. 2017 Aug 8;7(1):7495. doi: 10.1038/s41598-017-07181-0.

23.

Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to α-synuclein targeted disease modification.

Ko WKD, Bezard E.

Exp Neurol. 2017 Dec;298(Pt B):172-179. doi: 10.1016/j.expneurol.2017.07.020. Epub 2017 Jul 29. Review.

PMID:
28764902
24.

Decreased Rhes mRNA levels in the brain of patients with Parkinson's disease and MPTP-treated macaques.

Napolitano F, Booth Warren E, Migliarini S, Punzo D, Errico F, Li Q, Thiolat ML, Vescovi AL, Calabresi P, Bezard E, Morelli M, Konradi C, Pasqualetti M, Usiello A.

PLoS One. 2017 Jul 25;12(7):e0181677. doi: 10.1371/journal.pone.0181677. eCollection 2017.

25.

A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.

Ko WKD, Li Q, Cheng LY, Morelli M, Carta M, Bezard E.

Eur J Pharmacol. 2017 Oct 15;813:10-16. doi: 10.1016/j.ejphar.2017.07.030. Epub 2017 Jul 21.

PMID:
28739086
26.

Alterations in Functional Cortical Hierarchy in Hemiparkinsonian Rats.

Jávor-Duray BN, Vinck M, van der Roest M, Bezard E, Berendse HW, Boraud T, Voorn P.

J Neurosci. 2017 Aug 9;37(32):7669-7681. doi: 10.1523/JNEUROSCI.3257-16.2017. Epub 2017 Jul 7.

27.

Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy.

Bassil F, Guerin PA, Dutheil N, Li Q, Klugmann M, Meissner WG, Bezard E, Fernagut PO.

Mov Disord. 2017 Aug;32(8):1230-1239. doi: 10.1002/mds.27041. Epub 2017 May 29.

PMID:
28556404
28.

Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia.

Bastide MF, Glangetas C, Doudnikoff E, Li Q, Bourdenx M, Fernagut PO, Dumont ÉC, Georges F, Bézard E.

Sci Rep. 2017 May 24;7(1):2348. doi: 10.1038/s41598-017-02572-9.

29.

Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration.

Soria FN, Engeln M, Martinez-Vicente M, Glangetas C, López-González MJ, Dovero S, Dehay B, Normand E, Vila M, Favereaux A, Georges F, Lo Bianco C, Bezard E, Fernagut PO.

Hum Mol Genet. 2017 Jul 15;26(14):2603-2615. doi: 10.1093/hmg/ddx120.

PMID:
28520872
30.

In vitro α-synuclein neurotoxicity and spreading among neurons and astrocytes using Lewy body extracts from Parkinson disease brains.

Cavaliere F, Cerf L, Dehay B, Ramos-Gonzalez P, De Giorgi F, Bourdenx M, Bessede A, Obeso JA, Matute C, Ichas F, Bezard E.

Neurobiol Dis. 2017 Jul;103:101-112. doi: 10.1016/j.nbd.2017.04.011. Epub 2017 Apr 11.

PMID:
28411117
31.

U18666A, an activator of sterol regulatory element binding protein pathway, modulates presynaptic dopaminergic phenotype of SH-SY5Y neuroblastoma cells.

Schmitt M, Dehay B, Bezard E, Garcia-Ladona FJ.

Synapse. 2017 Sep;71(9). doi: 10.1002/syn.21980. Epub 2017 Jun 20.

PMID:
28407359
32.

Lack of spontaneous age-related brain pathology in Octodon degus: a reappraisal of the model.

Bourdenx M, Dovero S, Thiolat ML, Bezard E, Dehay B.

Sci Rep. 2017 Apr 4;7:45831. doi: 10.1038/srep45831.

33.

Insulin resistance and exendin-4 treatment for multiple system atrophy.

Bassil F, Canron MH, Vital A, Bezard E, Li Y, Greig NH, Gulyani S, Kapogiannis D, Fernagut PO, Meissner WG.

Brain. 2017 May 1;140(5):1420-1436. doi: 10.1093/brain/awx044.

34.

Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate.

Migdalska-Richards A, Ko WKD, Li Q, Bezard E, Schapira AHV.

Synapse. 2017 Jul;71(7). doi: 10.1002/syn.21967. Epub 2017 Mar 17.

35.

Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update.

Voon V, Napier TC, Frank MJ, Sgambato-Faure V, Grace AA, Rodriguez-Oroz M, Obeso J, Bezard E, Fernagut PO.

Lancet Neurol. 2017 Mar;16(3):238-250. doi: 10.1016/S1474-4422(17)30004-2. Epub 2017 Feb 15. Review.

PMID:
28229895
36.

Exosomes, an Unmasked Culprit in Neurodegenerative Diseases.

Soria FN, Pampliega O, Bourdenx M, Meissner WG, Bezard E, Dehay B.

Front Neurosci. 2017 Jan 31;11:26. doi: 10.3389/fnins.2017.00026. eCollection 2017. Review.

37.

Endosulfine-alpha inhibits membrane-induced α-synuclein aggregation and protects against α-synuclein neurotoxicity.

Ysselstein D, Dehay B, Costantino IM, McCabe GP, Frosch MP, George JM, Bezard E, Rochet JC.

Acta Neuropathol Commun. 2017 Jan 10;5(1):3. doi: 10.1186/s40478-016-0403-7.

38.

Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice.

Migdalska-Richards A, Daly L, Bezard E, Schapira AH.

Ann Neurol. 2016 Nov;80(5):766-775. doi: 10.1002/ana.24790.

39.

A brain-spine interface alleviating gait deficits after spinal cord injury in primates.

Capogrosso M, Milekovic T, Borton D, Wagner F, Moraud EM, Mignardot JB, Buse N, Gandar J, Barraud Q, Xing D, Rey E, Duis S, Jianzhong Y, Ko WK, Li Q, Detemple P, Denison T, Micera S, Bezard E, Bloch J, Courtine G.

Nature. 2016 Nov 10;539(7628):284-288. doi: 10.1038/nature20118.

40.

LC-MS/MS-based quantification of kynurenine metabolites, tryptophan, monoamines and neopterin in plasma, cerebrospinal fluid and brain.

Fuertig R, Ceci A, Camus SM, Bezard E, Luippold AH, Hengerer B.

Bioanalysis. 2016 Sep;8(18):1903-17. doi: 10.4155/bio-2016-0111. Epub 2016 Aug 15.

41.

Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy.

Bassil F, Fernagut PO, Bezard E, Pruvost A, Leste-Lasserre T, Hoang QQ, Ringe D, Petsko GA, Meissner WG.

Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):9593-8. doi: 10.1073/pnas.1609291113. Epub 2016 Aug 1.

42.

An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models.

Ko WKD, Camus SM, Li Q, Yang J, McGuire S, Pioli EY, Bezard E.

Neuropharmacology. 2016 Nov;110(Pt A):48-58. doi: 10.1016/j.neuropharm.2016.07.012. Epub 2016 Jul 14.

PMID:
27424102
43.

Is near-infrared light neuroprotective?

Bezard E.

Ann Neurol. 2016 Aug;80(2):310. doi: 10.1002/ana.24698. Epub 2016 Jun 24. No abstract available.

PMID:
27273753
44.

M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.

Shen W, Plotkin JL, Francardo V, Ko WK, Xie Z, Li Q, Fieblinger T, Wess J, Neubig RR, Lindsley CW, Conn PJ, Greengard P, Bezard E, Cenci MA, Surmeier DJ.

Neuron. 2016 Jun 1;90(5):1139. doi: 10.1016/j.neuron.2016.05.017. No abstract available.

45.

Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy.

Engeln M, Ansquer S, Dugast E, Bezard E, Belin D, Fernagut PO.

Neuropharmacology. 2016 Oct;109:69-77. doi: 10.1016/j.neuropharm.2016.05.013. Epub 2016 May 20.

46.

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.

Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S, Bezard E, Poli SM, Goetz CG, Trenkwalder C, Rascol O.

Mov Disord. 2016 Sep;31(9):1373-80. doi: 10.1002/mds.26659. Epub 2016 May 23.

PMID:
27214664
47.

MitoBrain, Putting energy into the brain.

Benard G, Bezard E, Marsicano G, Pouvreau S.

Neurobiol Dis. 2016 Jun;90:1-2. doi: 10.1016/j.nbd.2016.03.021. No abstract available.

PMID:
27067181
48.

Targeting α-synuclein: Therapeutic options.

Dehay B, Decressac M, Bourdenx M, Guadagnino I, Fernagut PO, Tamburrino A, Bassil F, Meissner WG, Bezard E.

Mov Disord. 2016 Jun;31(6):882-8. doi: 10.1002/mds.26568. Epub 2016 Mar 1. Review.

PMID:
26926119
49.

Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.

Pinna A, Ko WK, Costa G, Tronci E, Fidalgo C, Simola N, Li Q, Tabrizi MA, Bezard E, Carta M, Morelli M.

Mov Disord. 2016 Apr;31(4):501-11. doi: 10.1002/mds.26475. Epub 2016 Feb 12.

PMID:
26871939
50.

Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.

Arcuri L, Viaro R, Bido S, Longo F, Calcagno M, Fernagut PO, Zaveri NT, Calò G, Bezard E, Morari M.

Neurobiol Dis. 2016 May;89:55-64. doi: 10.1016/j.nbd.2016.01.016. Epub 2016 Jan 22.

Supplemental Content

Loading ...
Support Center